Bioidentical hormones vs standard HRT: what is the difference?

Short answer

• “Bioidentical hormones” describes hormones that are chemically identical to human hormones (usually estradiol, estrone, progesterone, testosterone). They can be supplied as FDA‑approved pharmaceutical products or as custom‑made (compounded) preparations.
• “Standard HRT” commonly refers to conventional hormone therapy used for menopause that may include FDA‑approved bioidentical hormones (like estradiol) or non‑bioidentical/synthetic hormones (conjugated equine estrogens such as Premarin, or synthetic progestins such as medroxyprogesterone/Provera).
• Evidence does not show that compounded “bioidentical hormone replacement therapy” (BHRT) is safer or more effective than standard, FDA‑approved HRT. Choice should be based on the hormone type, dose, route, individual risks, and quality control.

Key differences

• Chemistry: Bioidentical = same molecular structure as human hormones. Synthetic HRT sometimes uses hormones that differ structurally (e.g., some progestins, conjugated equine estrogens).
• Regulation and consistency: FDA‑approved products undergo batch testing, standard labeling, and clinical trials. Compounded BHRT is made to order by pharmacies and is not FDA‑approved; potency, purity and stability can vary.
• Evidence: Large trials and guidelines (e.g., The North American Menopause Society, FDA) are based mainly on FDA‑approved therapies. There is no high‑quality evidence that compounded BHRT reduces the long‑term risks shown in trials (breast cancer, cardiovascular events, VTE) compared with equivalent FDA‑approved hormones.
• Monitoring and testing: Some practitioners who prescribe compounded BHRT rely on saliva testing or custom titration; these tests are generally unreliable for dose titration. Clinical symptoms and appropriate safety monitoring are preferred.

Typical options and examples

• FDA‑approved bioidentical estrogen products: Estrace (oral estradiol), Vivelle‑Dot/Climara/Alora (estradiol patches), EstroGel (estradiol gel in some markets). These give consistent dosing and known safety data.
• FDA‑approved bioidentical progesterone: Prometrium (micronized progesterone). Micronized progesterone may have different effects/side‑effect profile than synthetic progestins (e.g., medroxyprogesterone).
• Common non‑bioidentical standard HRT: Premarin (conjugated equine estrogens), Provera (medroxyprogesterone acetate), Prempro (combination product). These were used in major trials (e.g., WHI), so their risks are well documented.

Safety & evidence highlights

• Risks (breast cancer, blood clots, stroke, heart disease) depend on hormone type, dose, route (oral vs transdermal), duration, and individual risk factors (age, smoking, history of VTE, breast cancer risk).
• Transdermal estradiol may have lower VTE risk than oral estrogens in some studies. Micronized progesterone may have a different safety profile than some synthetic progestins, but data are not definitive for all endpoints.
• “Natural” or “bioidentical” labeling does not guarantee safer.

When compounded BHRT is considered

• Compounded BHRT may be used when a patient has a documented intolerance or allergy to available FDA products or needs a dose/formulation not commercially available.
• If you go the compounded route, use a reputable compounding pharmacy with USP compliance and state licensure, and work with a clinician experienced in menopause care.

Practical recommendations

• Prefer FDA‑approved bioidentical products when you want a bioidentical hormone because they provide consistent dosing and established safety data (examples: Vivelle‑Dot or Climara patches for estradiol; Estrace for oral estradiol; Prometrium for progesterone).
• Discuss specific risks and benefits with a clinician (OB/GYN, family physician, or a NAMS‑certified menopause practitioner). Ask about alternatives, dose, route, monitoring plan, and duration.
• Avoid relying on saliva hormone testing to adjust therapy. Use symptom response and appropriate labs/clinical monitoring.
• If considering a compounding pharmacy, ask about USP accreditation, lot testing, and oversight by a licensed pharmacist.

Where to get reliable information

• The North American Menopause Society (NAMS) and the FDA provide evidence‑based patient information and clinical guidance about hormone therapy.

If you want, tell me whether you’re asking for menopause HRT, transgender care, or another context and any priorities (e.g., minimize clot risk, avoid synthetic progestins, prefer non‑oral routes), and I’ll give more specific options and what to discuss with your clinician.